9/27/2006

Millennium Pharmaceuticals agreed to pay $515 million to acquire AnorMED, besting Genzyme Corp.'s bid to buy the Canadian biotech firm. The deal gives Millennium rights to AnorMED's blood-cancer therapy Mozobil, which is in late-stage clinical trials.

Related Summaries